Dopamine Articles
Teva's Azilect gets first approval in Israel
10 January 2005
Movement disorders market $2B in 2004
11 October 2004
Prestwick's tetrabenazine on FDA fast-track
27 September 2004
Positive data for Teva's Agilect
13 September 2004
Pfizer's Geodon gets FDA OK for new use
30 August 2004
Merck & Co licenses DOV's antidepressants
16 August 2004
Solvay's bifeprunox to see peak sales of $1B
14 June 2004
Anti-alcohol consumption patch in development
26 April 2004
Global peripheral neuropathy market worth $1B by 2012
19 April 2004
Green light for 150mg Wellbutrin generics
29 March 2004
UK NHS to offer free IVF treatment
1 March 2004
Solvay and Lundbeck move bifeprunox into Ph III
15 September 2003
Merck & Co licenses dopamine stabilizers from Carlsson
17 March 2003
Solvay updates on R&D progress
24 February 2003
Italy's Newron reports progress in Parkinson's
13 January 2003
Addex buys shelved CeNeS drug for $4.5M
6 January 2003
Parkinson's drugs may slow progression
22 April 2002
NeuroSearch and GSK drop antidepressant
11 March 2002
Pfizer to launch Zeldox in other EU markets
4 March 2002
Kyowa says Parkinson's drug trials are promising
25 February 2002
Boeh Ingelheim in $80m deal to develop NeuroSearch drug
18 February 2002
Aderis Pharma plans $100 million IPO.
21 January 2002
Pramipexole cleared as monotherapy in PD
26 November 2001
Pharmacia's Somavert works in acromegaly
26 November 2001
Shire licenses Parkinson's drug from DevCo
20 November 2001
Oxford BioMedica lifted by Parkinson's therapy
13 November 2001
B-MS and Otsuka submit aripiprazole
8 November 2001
Amarin revenues jump 191%
30 October 2001
Boston develops ADHD diagnostic
15 October 2001
AstraZeneca: Crestor filed, Viozan pulled
28 June 2001
Japan pharma stock market, week to June 25
27 June 2001
Spheramine effective in Parkinson's disease
17 May 2001
B-MS to file NDA for Abilitat in 4th quarter
27 April 2001
Pharmacia files for follow-up COX-2 OK
23 March 2001
CPMP backs first oral ED drug, apomorphine
26 January 2001
Neurologists favor dopamine agonists for Parkinson's
24 January 2001
Pharmacia/BI's Mirapex shows less risk of motor complications
19 October 2000
Novartis/Orion seek entacapone use in early Parkinson's disease
18 October 2000
Teva progresses in CNS and autoimmune drugs
31 July 2000
Pharmacia's DAs as first-line therapy in PD
20 June 2000
Stock Commentary Tokyo
15 June 2000
B-MS reveals Ph III aripiprazole data
17 May 2000
Parkinson's market "may double by 2008"
22 February 2000
Titan and Schering AG strike deal for PD therapy
3 February 2000
NeuroSearch signs $47m deal with GW
24 January 2000
Schwarz Pharma boosts CNS pipeline
29 December 1999
AstraZeneca unveils promising portfolio with 57 NCEs
14 December 1999
DevCo Pharmaceuticals completes Ph II with Parkinson's drug
29 November 1999
NeuroSearch to begin Phase II with AD drug
28 October 1999
B-MS, Otsuka link up on new antipsychotic
22 September 1999
NeuroSearch depression drug key to future success?
8 September 1999
New therapy for cocaine addiction?
5 August 1999
TAP files for Viagra competitor in USA
2 July 1999
Euro neurodegenerative disease markets
24 February 1999
Neurodegenerative disease markets in Europe
19 February 1999
Gene therapy obviates need for L-dopa in PD
5 February 1999
Novartis' iloperidone in Phase III in USA
21 January 1999
J&J To Cut 4,100 Jobs, Taking $800 Million Charge
8 December 1998
SB's Requip Effective Parkinson's Adjunct
29 October 1998
SmithKline Beecham's Requip Effective Parkinson's Adjunct
23 October 1998
UK Approval For BASF/Knoll's Zotepine
8 October 1998
Evolution In Migraine Therapy; New Triptans, And Beyond
10 September 1998
Novartis Starts Phase III Iloperidone Trials
20 August 1998
Chiesi Aims For Top 20 Place In Italian Market
5 August 1998
High Hopes For HMR's Novel Antipsychotic
15 July 1998
FDA Says Pfizer's Zeldox Is "Non-Approvable"
24 June 1998
Viagra Still Riding High, But Competition Looms
15 June 1998
FDA Panel Votes Against Ergoset Recommendation
21 May 1998
Requip May Preserve Function In Parkinson's
13 May 1998
J&J Invests In Ergo Sciences
15 April 1998
Pramipexole Approved In The European Union
5 March 1998
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
